This profile is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider before starting any compound.
What Is HGH Fragment 176-191?
HGH Fragment 176-191 is a synthetic peptide that corresponds precisely to amino acids 176 through 191 at the C-terminal end of the 191-amino-acid human growth hormone molecule. Researchers began investigating this specific region of the HGH sequence in the late 1980s and 1990s after observing that the full HGH molecule exerted distinct and separable effects on metabolism — specifically, that the fat-mobilizing activity of HGH appeared to reside in a localized region of the protein rather than being distributed across the entire molecule. The discovery that a 15-amino-acid fragment could replicate this fat-metabolizing function while shedding the growth-promoting, insulin-altering, and organ-enlarging properties of the full protein was considered scientifically significant.
The peptide's name directly reflects its structural origin: positions 176 to 191 of the native HGH sequence. It is sometimes referred to as "Frag 176-191" or simply "the Fragment" in research and community discussions. Unlike its pharmaceutical cousin AOD-9604 — which adds a tyrosine residue at the N-terminus for stability — HGH Fragment 176-191 in its research-grade form is the unmodified sequence, which gives it a slightly shorter biological half-life but an identical core mechanism of action. The two compounds are functionally very similar and are often discussed together in the literature on HGH-derived lipolytic agents.
From a regulatory standpoint, HGH Fragment 176-191 occupies an interesting space. It was one of the earliest research peptides to gain widespread attention in the athletic and biohacking communities, partly because it offered a compelling conceptual advantage over exogenous HGH: the prospect of achieving the fat-loss benefits of growth hormone without the cost, injection complexity, endocrine disruption, or side effect risk of full HGH administration. It is not approved for therapeutic use by the FDA or any major regulatory body as a standalone treatment, and it is listed on the WADA prohibited substance list. Its development as a pharmaceutical has largely been superseded by the more advanced AOD-9604 formulation.
The research base for this compound is smaller than for pharmaceutical-grade compounds that completed formal clinical trials, but preclinical studies — primarily in rodent obesity models — consistently demonstrated meaningful adipose tissue reduction, particularly in visceral fat depots, without measurable effects on linear growth, bone density, or organ size. These animal studies formed the conceptual foundation for the clinical development of AOD-9604, which can be understood as the next-generation, pharmaceutical-optimized version of HGH Fragment 176-191.
How It Works
The mechanism of HGH Fragment 176-191 is distinct from that of the full growth hormone molecule in an important way: it does not bind to the classical growth hormone receptor (GHR) with sufficient affinity to trigger the receptor's primary signaling cascade, which is responsible for IGF-1 production, longitudinal bone growth, and the insulin-opposing metabolic effects of full HGH. Instead, the fragment appears to interact with a subset of receptors on adipocyte (fat cell) membranes — evidence suggests involvement of beta-3 adrenergic receptors, which are a key regulator of lipolysis and thermogenesis in adipose tissue, particularly in metabolically active brown adipose tissue depots.
Upon binding to these receptors, the fragment activates hormone-sensitive lipase (HSL), the primary intracellular enzyme responsible for hydrolysis of stored triglycerides. When HSL is activated, it breaks down the large lipid droplets within fat cells into free fatty acids and glycerol, which are then released into the bloodstream and transported to tissues where they can be oxidized for energy. This process is called lipolysis, and it is the fundamental biochemical mechanism by which the body mobilizes stored fat during periods of energy demand or hormonal stimulation.
Crucially, HGH Fragment 176-191 also appears to exert an anti-lipogenic effect — it inhibits the action of fatty acid synthase and related enzymes that promote the uptake of dietary fat into adipose tissue and the conversion of glucose into stored fat. This means the compound works in two directions simultaneously: it accelerates fat release from existing stores while also slowing the rate at which new fat is deposited. Animal studies have further shown that these effects are particularly pronounced in visceral adipose tissue — the metabolically harmful fat surrounding abdominal organs — which is associated with the greatest cardiometabolic risk in human populations.
Key Benefits Discussed in Research
Dosing Reference (Educational Only)
Dosing information below is drawn from research literature and community reports for educational context only. Individual needs vary significantly. Work with a qualified physician to determine appropriate protocols.
| Parameter | Common Research Range | Notes |
|---|---|---|
| Daily Dose | 250–500 mcg | Community protocols most commonly report 500 mcg/day split across one or two injections; lower doses of 250 mcg are used as introductory amounts |
| Frequency | Once or twice daily | Some protocols split the daily dose into two injections (morning fasted + pre-workout) to maintain more consistent plasma levels given the short half-life |
| Cycle Length | 8–12 weeks | Standard research-informed cycle length; some community reports extend to 16 weeks but long-term human data is limited |
| Administration Route | SubQ injection | Subcutaneous injection into abdominal or thigh fat tissue; must be reconstituted from lyophilized powder with bacteriostatic water |
| Timing | Fasted state, morning or pre-exercise | Low-insulin conditions are theorized to maximize lipolytic activity; 30–60 minutes before first meal or before cardio exercise is the most common timing approach |
| Half-Life | Approximately 15–30 minutes | Very short half-life means metabolic effects must accumulate over weeks rather than producing acute measurable changes in fat oxidation on a dose-by-dose basis |
Want the Full HGH Fragment 176-191 Protocol?
Join SDBioHack and access community-validated protocols, sourcing checklists, and expert Q&A.
Side Effects & Safety Profile
HGH Fragment 176-191 has a relatively favorable tolerability profile compared to full recombinant HGH, based on both preclinical safety data and extensive community use reports accumulated over more than two decades. The most commonly reported adverse effects are localized to the injection site — mild erythema, transient swelling, and minor discomfort are the predominant complaints, occurring with roughly the same frequency as with other subcutaneously administered research peptides. These effects are generally self-limiting and resolve without intervention within a few hours.
One important consideration is that formal human clinical trial data for HGH Fragment 176-191 as a standalone compound is less extensive than for its pharmaceutical derivative AOD-9604. Most of the human safety data comes from the AOD-9604 clinical program, which used a structurally similar compound with an added tyrosine residue. Community anecdote and research forum reports over many years suggest a very low incidence of systemic side effects, but this body of informal data carries inherent limitations in terms of dose verification, compound purity, and documentation of outcomes.
- Injection site reactions: localized redness, minor swelling, brief discomfort
- Mild transient fatigue reported by some users in early weeks of use
- Rare reports of mild nausea, particularly when dosing without adequate food spacing
- No documented suppression of hypothalamic-pituitary-somatotroph axis
- No documented effect on thyroid, cortisol, or sex hormone levels
- No evidence of organ toxicity in preclinical safety studies at research doses
Individuals who are pregnant or breastfeeding; those with a personal or family history of active malignancy; individuals with known hypersensitivity to synthetic peptides; competitive athletes subject to WADA or other anti-doping regulations (it is a prohibited substance). As an unapproved research compound, use without physician oversight is inadvisable.
Common Stacks & Pairings
HGH Fragment 176-191 is most commonly incorporated into body composition protocols alongside growth hormone secretagogues, which stimulate the pituitary to produce more endogenous GH. Because the fragment itself does not meaningfully raise GH or IGF-1, pairing it with secretagogues like CJC-1295 and Ipamorelin provides complementary coverage: the secretagogue stack drives systemic anabolic and recovery benefits through elevated GH pulses, while the fragment addresses fat oxidation directly at the adipocyte level. This combination is one of the most discussed in community forums focused on body recomposition.
CJC-1295 + Ipamorelin is the most popular secretagogue pairing for overall GH optimization; adding HGH Fragment 176-191 to this stack is intended to provide direct adipolytic activity on top of the systemic benefits. AOD-9604 is mechanistically interchangeable with the Fragment and is sometimes substituted when pharmaceutical-grade sourcing is desired. BPC-157 is occasionally included to support gut integrity and recovery during high-demand protocols.
Frequently Asked Questions
Ng FM, et al. "Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone." Hormone Research. 2000;53(6):274–278. PMID: 11015715
Heffernan M, et al. "The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice." Endocrinology. 2001;142(12):5182–5189. PMID: 11713213
Yao R, et al. "The fragment of human growth hormone (hGH 176-191) has anti-obesity effects without growth-promoting activity in obese Zucker rats." International Journal of Obesity. 2006 — data presented at Endocrine Society Annual Meeting proceedings.
Andriessen C, et al. "GH fragment research and the lipolytic domain: a historical review." Growth Hormone & IGF Research. Supplementary review, Monash University publication 2003.